Press coverage about Versartis (NASDAQ:VSAR) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Versartis earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 48.6287729128133 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Several equities analysts have issued reports on VSAR shares. Cantor Fitzgerald set a $14.00 target price on Versartis and gave the company a “buy” rating in a research note on Friday, October 27th. Zacks Investment Research lowered Versartis from a “hold” rating to a “sell” rating in a research note on Sunday, January 21st. Two analysts have rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the company’s stock. Versartis has an average rating of “Hold” and an average target price of $5.63.
Versartis (NASDAQ VSAR) opened at $1.80 on Tuesday. Versartis has a twelve month low of $1.60 and a twelve month high of $24.00. The stock has a market capitalization of $60.88, a P/E ratio of -0.46 and a beta of 2.11. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52.
In other Versartis news, Director Srinivas Akkaraju bought 419,700 shares of Versartis stock in a transaction dated Friday, December 1st. The stock was acquired at an average cost of $2.13 per share, with a total value of $893,961.00. Following the purchase, the director now directly owns 14,955 shares in the company, valued at approximately $31,854.15. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Jay Shepard sold 14,446 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $1.80, for a total value of $26,002.80. Following the transaction, the insider now directly owns 602,298 shares of the company’s stock, valued at $1,084,136.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,400 shares of company stock valued at $38,520. Corporate insiders own 10.90% of the company’s stock.
WARNING: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-versartis-vsar-share-price.html.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.